Citius Pharmaceuticals Inc expected to post a loss of 5 cents a share - Earnings Preview

Citius Pharmaceuticals

07/08/2023 13:57

* Citius Pharmaceuticals Inc  CTXR.OQ   CTXR.O  is expected
to show no change in quarterly revenue when it reports 
results on August 9 (estimated). 
    * 
    * ​Refinitiv's mean analyst estimate for Citius
Pharmaceuticals
Inc is for a loss of 5 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Citius
Pharmaceuticals Inc is $4​, above​ its last closing price
of $0.92. ​​​

This summary was machine generated August 7 at 12:57 GMT.  All
figures in US dollars  unless otherwise stated